Clinical trials: Dual Antiplatelet Therapy
Coronary Artery Disease
The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent
PIONEER-IV is a prospective, single-blind (patient), randomized, 1:1, controlled, multi-center study comparing clinical outcomes between angiography-derived physiology guidance to LRDP and usual care in an all-comers patient…
- Trial name
- PIONEER-IV (NCT04923191)
- Testing
- Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care
- Where
- 19 sites in Belgium, Ireland and 3 more
- Volunteers
- 2,540 people
- Sponsor
- National University of Ireland, Galway, Ireland
Coronary Artery Disease, Percutaneous Coronary Intervention
Ethnic Differences and the Ischemia/Bleeding Risk of DAPT Duration
this study is an individual patient level meta-analysis of randomized clinical trials, to evaluate the influence of ethnicity, to study whether the relative tradeoff between ischemia and bleeding is distinct by ethnicity.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
- Trial name
- NCT03338335
- Testing
- prolonged DAPT
- Where
- South Korea
- Volunteers
- 16,000 people
- Sponsor
- Seoul National University Hospital
Acute Coronary Syndrome
DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid
Among patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) and stent implantation, 17.5% are both at high bleeding risk (HBR) and have undergone complex PCI, which also places them at…
- Trial name
- BETA-DAPT (NCT07391358)
- Testing
- Patient decision aid to support shared decision-making between patients and clinicians
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- Montreal Heart Institute
Coronary Artery Disease
The Dual Antiplatelet Therapy Study (DAPT Study)
The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety…
- Trial name
- NCT00977938
- Testing
- Clopidogrel & Aspirin, Prasugrel & Aspirin
- Where
- 256 sites in United States, Australia and 8 more
- Volunteers
- 25,682 people
- Sponsor
- Baim Institute for Clinical Research
Peripheral Arterial Disease
Cilostazol Following Peripheral Endovascular Procedures
To compare the safety and effectiveness of dual anti-platelet therapy with cilostazol 100 mg twice daily and aspirin 100 mg daily versus monotherapy with aspirin 100 mg daily in patients undergoing peripheral angioplasty or…
- Trial name
- CILO-PER (NCT02770274)
- Testing
- Cilostazol, Aspirin
- Where
- 2 sites in Greece
- Volunteers
- 200 people
- Sponsor
- Attikon Hospital
Coronary Artery Disease
SAPT Versus DAPT in Incomplete Revascularization After CABG
The study aims to compare the efficacy of dual antiplatelet therapy (DAPT) over single antiplatelet therapy (SAPT) in patients with incomplete revascularization after coronary artery bypass graft surgery (CABG).
- Trial name
- SDAT-IRC (NCT03789916)
- Testing
- Ticagrelor, acetylsalicylic acid
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- Campus Bio-Medico University
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), High Bleeding Risk
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR
The aim of this study is to assess the safety and efficacy of the CYP2C19 genotype-guided abbreviated dual antiplatelet therapy (DAPT) strategy versus the un-guided stepwise intensity de-escalation of DAPT strategy in patients…
- Trial name
- GUIDE-HBR (NCT06763744)
- Testing
- P2Y12 antagonist monotherapy, clopidogrel + aspirin
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Samsung Medical Center
Multi Vessel Coronary Artery Disease
Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass
Ticagrelor, a direct-acting oral P2Y12-receptor antagonist, provides greater and more consistent platelet inhibition than clopidogrel.
- Trial name
- NCT05166538
- Testing
- Ticagrelor, Clopidogrel
- Where
- South Korea
- Volunteers
- 204 people
- Sponsor
- Yonsei University
Postoperative Bleeding
Platelet Inhibition and Bleeding in Patients Undergoing Non-Cardiac Surgery
The aim of the study is to evaluate if there is an association between platelet inhibition and surgery-related bleeding in patients undergoing non-cardiac surgery during dual antiplatelet therapy.
- Trial name
- BIANCA (NCT01606865)
- Where
- Austria
- Volunteers
- 207 people
- Sponsor
- Medical University of Graz
Coronary Artery Disease
Determination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents Versus Biolimus A9-eluting Stents
This study is a retrospective and prospective follow-up study of patients who were participating in a randomized comparative study (DETECT-OCT trial) to determine the duration of dual antiplatelet therapy for neointimal…
- Trial name
- NCT03873012
- Where
- South Korea
- Volunteers
- 894 people
- Sponsor
- Yonsei University
Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)
The primary aim of this study is to investigate the PD effects of switching from standard-dose clopidogrel dose to low-dose prasugrel versus continuing standard-dose clopidogrel in patients at dual-risk (HBR defined as the…
- Trial name
- NCT07025148
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Florida
Percutaneous Coronary Intervention
A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI
This is a multi-center, randomized, double-blind, triple-dummy, clopidogrel-controlled study of IV and oral PRT060128 compared to clopidogrel in patients undergoing non-urgent (including elective) PCI.
- Trial name
- INNOVATE-PCI (NCT00751231)
- Testing
- clopidogrel, PRT060128
- Where
- 59 sites in United States, Austria and 3 more
- Volunteers
- 652 people
- Sponsor
- Portola Pharmaceuticals
Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors
Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions
The use of aspirin combined with a P2Y12 inhibitor (dual antiplatelet therapy, DAPT) represents the standard of care for patients undergoing percutaneous coronary intervention (PCI) with stent implantation.
- Conditions
- Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Coronary Artery Disease
- Trial name
- TAILOR-DAPT (NCT05732701)
- Testing
- Algorithm-guided DAPT duration, Standard-of-care DAPT duration
- Where
- 4 sites in Bosnia and Herzegovina, Italy and 1 more
- Volunteers
- 2,788 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Ischemic Heart Disease, Coronary Artery Disease
Prospective Registry of Patients Over 75 Years Old Treated With Xience Sierra Stents. Sierra 75 Study
This prospective registry is intended to evaluate the safety and efficacy of the XIENCE Sierra stent.
- Trial name
- SIERRA 75 (NCT03567733)
- Testing
- XIENCE Sierra
- Where
- 44 sites in Portugal, Spain
- Volunteers
- 1,000 people
- Sponsor
- Fundación EPIC
Coronary Artery Lesions
XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
XIENCE 90 study is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary…
- Trial name
- NCT03218787
- Testing
- XIENCE, DAPT
- Where
- 101 sites in United States
- Volunteers
- 2,047 people
- Sponsor
- Abbott Medical Devices
Transient Ischemic Attacks, Minor Stroke
The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack
The primary goal of the research is to determine if 10 days of dual anti-platelet treatment is as effective as 30 days of similar treatment in the prevention of stroke, myocardial ischemia (MI) and death in patients with TIAs and…
- Trial name
- MENA-TIA (NCT02144831)
- Testing
- anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
- Where
- Canada
- Sponsor
- University of Alberta
Bleeding
Evaluation of Platelet Aggregability in the Release of CABG in Patients With ACS With DAPT.
The purpose of this study is to assess platelet aggregability by a "point of care" device (Multiplate®) to decrease the release time for coronary artery bypass graft (CABG ) in patients with acute coronary syndrome (ACS) in use…
- Trial name
- NCT02516267
- Testing
- Multiplate ADP®
- Where
- Brazil
- Volunteers
- 190 people
- Sponsor
- University of Sao Paulo General Hospital
Acute Coronary Syndrome, Myocardial Infarction
Future Optimal Research and Care Evaluation
Rationale: Acute coronary syndrome (ACS) is the leading cause of death worldwide. To improve cardiovascular care, research is needed.
- Trial name
- FORCE-ACS (NCT03823547)
- Where
- 4 sites in Netherlands
- Volunteers
- 99,999 people
- Sponsor
- J.M. ten Berg
Optical Coherence Tomography, Dual Antiplatelet Therapy
OCT or Angiography Guided De-escalation of DAPT
Optical coherence tomography (OCT) offers a high-resolution intravascular imaging modality to accurately assess vessel and lumen geometry and identify the hallmark of a culprit lesion including plaque disruption and thrombus.
- Conditions
- Optical Coherence Tomography, Dual Antiplatelet Therapy, Antiplatelet De-escalation, Neointimal Coverage
- Trial name
- NCT06339021
- Testing
- OCT-guided PCI, Conventional angiography-based PCI, DAPT de-escalation
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shenyang Northern Hospital
Coronary Artery Disease, Acute Coronary Syndrome
Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT
Objective: To evaluate the safety of bioresorbable polymer-coated everolimus-eluting Synergy® stent followed by 1-month dual antiplatelet therapy in patients at high-bleeding risk.
- Trial name
- POEM (NCT03112707)
- Testing
- Aspirin, P2Y12 inhibitor
- Where
- Italy
- Volunteers
- 1,023 people
- Sponsor
- Humanitas Hospital, Italy